Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 19/20 | 0.72 |
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | BRAF | P15056 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 1/20 | 0.72 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1488785 | 1.00 | MAP2K2 (0.72) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL29413391 | 0.98 | MAP2K2 (0.76) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL1488415 | 0.98 | MAP2K2 (0.76) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL21010855 | 0.88 | MAP2K1 (0.62) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL1488789 | 0.87 | MAP2K1 (0.61) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL1488014 | 0.85 | MAP2K1 (0.95) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL30220976 | 0.85 | MAP2K1 (0.95) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL189480 | 0.85 | MAP2K1 (0.95) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL1488833 | 0.85 | MAP2K1 (0.95) | MAP2K2MAP2K1CHRM2CHRM1BRAF | |
| SCHEMBL29413486 | 0.85 | MAP2K1 (0.95) | MAP2K2MAP2K1CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | MAP2K2 51/4885MAP2K1 53/4885CHRM2 4559/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | MAP2K2 49/4885MAP2K1 52/4885CHRM2 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.